Posts Archive

IMROZ Study NCT03319667 Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not...

Multiple Myeloma Research Consortium NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory...

NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant A...

NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple...

NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma A Safety, PK and Efficacy Study of...

HORSHAM, PA, June 16, 2017 – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the...

Myeloma Canada: Multiple Myeloma Patient Handbook https://myeloma.ca/pixms/uploads/serve/ckeditor/myeloma_canada_patient_handbook_10_2017...

Phase II HOVON 143 Study Trial Update 63rd ASH Annual Meeting 80 Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit...

Multiple Myeloma Research Consortium NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Multiple...

GMMG - The German Speaking Myeloma Multicenter Group GMMG-CONCEPT trial Isa-KRd NCT03104842: Phase 2 - Evaluation iNduction,...

Cleveland Clinic: How to Give Subcutaneous Chemotherapy Injections

NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...

NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma...

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma NCT03338972: Phase 1...

(PRIME) NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) NCT03288493: Phase...

MajesTEC1 Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory...

NCT03218683: Phase 1/2: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies....

IKEMA Isa-Kd Vs Kd Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In...

Cancer related fatigue (CRF) is the most common cancer side effect and can severely interfere with activities of daily living long after...

Penn Medicine, the Abramson Cancer Center: CAR-T Cell Therapy: Using Healthy Cells to Fight Cancer Learn more:...

NCT03269136 MAGNETISMM-1 RRMM NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma To...

SITC - Society for Immunotherapy of Cancer IMMUNOTHERAPY: The Path to a Cancer Cure (For Patients) Learn more: Society for Immunotherapy...

Roswell Park Comprehensive Cancer Center REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients Feb 23, 2017...

NCT03078452: Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy...